IPO Report: Nexvet Biopharma plc (NVET)

Francis Gaskins |

nexvet biopharma IPO, nexvet biopharma IPO price, nexvet biopharma IPO date, IPOs this week, stocks to buy now, small-cap stocksNexvet Biopharma plc (NVET) is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics. It is based in Dublin, Ireland.

Ten other companies are scheduled to IPO for the week of Feb. 2, 2015. The full IPO calendar is available at IPOpremium.

Manager, Joint-managers: BofA Merrill Lynch and Cowen

Co-managers: Piper Jaffray and JMP Securities

End of lockup (180 days): Tuesday, August 4, 2015

End of 25-day quiet period: Monday, March 2, 2015

NVET scheduled a $58 million IPO with a market capitalization of $160 million at a price range midpoint of $14.50 for Thursday, Feb. 5, 2015 on Nasdaq.  SEC Documents

Nexvet Biopharma IPO Overview

NVET is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics.

As a class, biologics, which include mAbs and fusion proteins, have transformed human medicine in recent decades and represent some of the top-selling therapies on the market today.

Veterinary care is one of the fastest growing industries in the overall U.S. companion animal market and is estimated to reach $15.3 billion in 2014.

Nexvet Biopharma IPO Valuation

Glossary

Accumulated deficit (mm)

.

.

-$14

     

Per share dilution

.

.

-$7.54

     

-----------------------------------------------------------------------

     

Valuation Ratios

Mrkt Cap (mm)

Price /Sls

Price /Erngs

Price /BkVlue

Price /TanBV

% offered in IPO

annualizing Sept 9 mos

         

Nexvet Biopharma plc NVET)

$160

n/a

-22.6

2.1

2.1

36%

             

Nexvet Biopharma IPO: Conclusion

Neutral

Animal biologics

Insiders may purchase $12mm, 20.6%

Safety & efficacy data expected end of '15 and  '16

Price-to-bk 2.1, relatively low

P/E of -22.6 indicates relatively low current cash burn rate relative to market cap

Nexvet Biopharma Business

NVET is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics.

As a class, biologics, which include mAbs and fusion proteins, have transformed human medicine in recent decades and represent some of the top-selling therapies on the market today.

NVET is targeting the companion animal therapeutics segment of the veterinary care industry.

NVET estimates that in 2013 consumers spent $2.3 billion on companion animal therapeutics. This segment is currently dominated by small molecule drugs.

Nexvet Biopharma Market

Veterinary care is one of the fastest growing industries in the overall U.S. companion animal market and is estimated to reach $15.3 billion in 2014.

The size and growth of this market reflects many factors, including higher rates of companion animal ownership, increased availability and improved quality of veterinary care and the increasingly important role of companion animals in our lives, who are often considered members of our families.

NVET believes these factors, together with the introduction of its product candidates with their favorable safety and compliance profiles, will increase overall demand for companion animal therapeutics.

Two of NVET’s lead product candidates, NV-01 and NV-02, are mAbs that are designed to neutralize disease-causing targets in the body. mAbs belong to a class of medicines called biologics, which have transformed human medicine in recent decades.

They have had a significant impact in the treatment of a number of human conditions, including various cancers, inflammatory diseases and cardiovascular and neurological diseases.

As a class, mAbs have an improved safety and efficacy profile in humans over small molecule drugs.

Although a few have received conditional licensure in the United States, there are currently no mAbs for the management of pain or inflammation in companion animals approved for marketing in the United States or the EU.

Nexvet Biopharma Proprietary platform

NVET’s proprietary PETization platform is an algorithmic approach that enables NVET to rapidly create mAbs that are designed to be recognized as “self” or “native” by an animal’s immune system, a property NVET  refers to as “100% species-specificity.”

PETization is also designed to build upon the safety and efficacy data from clinically-tested human therapies to create new therapies for companion animals, thereby reducing clinical risk and development cost.

Nexvet Biopharma Two products

NVET’s first product candidate, NV-01, is a mAb that is a nerve growth factor, or NGF, inhibitor for the control of pain associated with osteoarthritis in dogs.

NVET’s second product candidate, NV-02, is a mAb that is an NGF inhibitor for the control of pain associated with degenerative joint disease in cats.

Nexvet Biopharma Data Expected

NVET expects data from its pivotal safety and efficacy studies for NV-01 by the end of 2015 and for NV-02 in 2016.

NVET’s third product candidate, NV-08, is a fusion protein that is a tumor necrosis factor, or TNF, inhibitor for the treatment of chronic inflammatory diseases, including atopic dermatitis, in dogs.

If its proof-of-concept safety and efficacy studies for NV-08 are successful, NVET will progress this product into formal development.

Nexvet Biopharma Growth Plan

Using PETization, NVET is seeking to advance one new product candidate into development per year, commencing in the second half of 2015.

Nexvet Biopharma Intellectual Property

NVET’s patent estate includes patent applications with claims directed to its PETization platform, its NV-01, NV-02 and NV-08 product candidate compositions, several of its pipeline product candidate compositions that are currently under development or are under consideration for future development and therapeutic uses of such product candidate compositions.

As of September 30, 2014, NVET’s patent estate included on a worldwide basis nine separate patent families with a total of approximately 99 pending patent applications, including approximately 90 pending foreign patent applications and nine pending patent applications in the United States.

Six of these patent families are directed to compositions and methods related to NVET’s mAb products currently in research or development.

These products have a novel combination of recipient compatibility and high affinity as a result of NVET’s innovative design process whereby the donor antibody is modified so that no amino acid in its variable or framework regions is foreign to the intended host in any position.

As a result, the therapeutic antibody is more likely to be seen as “self” or “native” and will therefore be less likely to induce a neutralizing antibody response.

This in turn will permit repeat dosing without reduction in efficacy or product half-life. Patents from these applications, if issued, are expected to expire between 2032 and 2035.

Nexvet Biopharma Competition

NVET believes its main competitors are animal health companies that are developing products for use in companion animals, such as Aratana Therapeutics, Inc., Kindred Biosciences, Inc. and Zoetis, Inc.

In addition, there are a number of large biopharmaceutical companies with animal health divisions, such as Bayer AG; Boehringer Ingelheim GmbH; Eli Lilly and Company (Elanco division); Merck & Co., Inc.; Sanofi S.A. (Merial division); and Novartis AG. If approved, NVET expects NV-01 and NV-02 will face competition from Deramaxx, marketed by Novartis; Metacam, marketed by Boehringer Ingelheim; Previcox, marketed by Merial; and Rimadyl, marketed by Zoetis, as well as from generic Meloxicam and Carprofen and other pain-treating products.

NVET believes that Kindred and Aratana are developing, and that other companies may develop, similar profile products as well.

In addition, private-label products may compete with NVET’s lead product candidates. If companion animal therapeutics customers increase their use of new or existing private-label products, NVET’s operating results and financial condition could be adversely affected.

Nexvet Biopharma 5% shareholders pre-IPO

David Gearing, Ph.D.    5.4%

Rajiv Patel        31.5%

Adage Capital Partners, LP        11.2%    

Akubra Investors, LLC  10.5%    

AustralianSuper Pty Ltd ATF AustralianSuper      6.3%      

Bushranger Funding, LLC           11.4% 

Foresite Capital Fund II, LP        9.9% 

Irrus Investments Nominee Limited         9.1%

One Funds Management Limited ATF Asia Pacific Healthcare Fund II       11.9% 

Ute Holdings, LLC         11.5%

Nexvet Biopharma Dividends

No dividends are planned.

Nexvet Biopharma Use of proceeds

NVET expects to receive $51 million from its IPO and use it for the following:

$4.0 million to complete its pivotal safety and efficacy studies for NV-01, its lead product candidate for the control of pain associated with osteoarthritis in dogs, plus an additional $9.0 million for chemistry, manufacturing and controls studies ($5.0 million), stability studies ($2.0 million), and regulatory compliance and other miscellaneous costs ($2.0 million); and

$13.0 to $15.0 million to complete the development and manufacturing scale-up of each of NV-02, its lead product candidate for the control of pain associated with degenerative joint disease in cats, and NV-08, its lead product candidate for the treatment of chronic inflammatory diseases, including atopic dermatitis, in dogs, which includes for each lead product candidate pivotal safety and efficacy studies ($4.0 million), chemistry, manufacturing and controls studies ($4.0 to $5.0 million), stability studies ($2.0 million), costs for proof-of-concept related activities ($1.0 million) and regulatory compliance and other miscellaneous costs ($2.0 to $3.0 million).

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
NVET Nexvet Biopharma plc 4.94 0.49 11.01 26,032

Comments

Emerging Growth

Naked Brand Group Inc

Naked Brand Group Inc through its wholly-owned subsidiary is engaged in manufacturing and selling of direct and wholesale men's undergarments to consumers and retailers.

Private Markets

Trustify

Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Cloudera

Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…